FIELD: medicine.
SUBSTANCE: present invention relates to the field of medicine; it is intended to cause antagonism of the orexin receptor activity in a patient, such as a mammal, requiring such inhibition. A pharmaceutical composition according to the invention contains: (1) 5 mg, 10 mg, 15 mg or 20 mg of suvorexant in an amorphous form; and (2) hydroxypropyl methylcellulose acetate-succinate (HPMCAS) or hydroxypropyl methylcellulose phthalate (HPMCP).
EFFECT: increase in the solubility and/or bioavailability of suvorexant.
9 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF SOLID DOSAGE FORMS OF AN OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2699358C2 |
| POLYMER COMPOSITIONS OF CETP INHIBITORS | 2007 |
|
RU2457841C2 |
| COMPOSITION OF THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | 2014 |
|
RU2661399C1 |
| COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION | 2008 |
|
RU2500398C2 |
| COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE | 2003 |
|
RU2356549C2 |
| METHOD FOR MELT GRANULATION | 2009 |
|
RU2491918C2 |
| METHOD FOR PREPARING SOLID DISPERSIONS OF HIGH CRYSTALLINE THERAPEUTIC COMPOUNDS | 2007 |
|
RU2454220C2 |
| DOSAGE FORMS WITH RETARDED RELEASE OF ZIPRASIDONE | 2004 |
|
RU2351316C2 |
| METHODS OF TREATING HEPATITIS C | 2013 |
|
RU2665365C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING UNSTABLE PLASTICISER | 2006 |
|
RU2430719C2 |
